| 29th Dec |
Appendix 3B |
| 29th Dec |
Change of Director's Interest Notice x 4 |
| 15th Dec |
Appendix 3B |
| 13th Dec |
Net Tangible Asset Backing |
| 8th Dec |
Appendix 3B |
| 8th Dec |
Eagle Begins Shipment of Omni Innovation’s Diabetes Product |
| 7th Dec |
Meluka Health to Develop Honey Water for Chinese Market |
| 6th Dec |
Eve Completes 50% Investment in Meluka Health |
| 1st Dec |
Appendix 3B |
| 1st Dec |
Change of Director's Interest Notice x 2 |
| 30th Nov |
Response to ASX Price & Volume Query |
| 27th Nov |
Change of Director’s Interest Notice |
| 27th Nov |
NSW Grant for Honey Research Successful |
| 27th Nov |
Appendix 3B |
| 23rd Nov |
Appendix 3Y |
| 22nd Nov |
Medic Honey Produces a Hemp Seed Honey |
| 22nd Nov |
Results of Annual General Meeting |
| 22nd Nov |
Prospectus |
| 22nd Nov |
Appendix 3B |
| 15th Nov |
Sydney Investor Roadshow Presentation |
| 14th Nov |
Net Tangible Asset Backing |
| 13th Nov |
Philip Owens Appointed CEO of Omni Innovation |
| 9th Nov |
Meluka Honey Branding and Marketing Commences |
| 6th Nov |
Supply Agreement with Large Producer of Australian Organic Honey |
| 2nd Nov |
Meluka Health Appoints Leading Bee And Honey Advisor |
| 31st Oct |
Eagle Commences Production of Omni Innovation’s Pre‐Meal Shake |
| 24th Oct |
Appendix 4C - Quarterly |
| 24th Oct |
Notice of Annual General Meeting and Proxy Form |
| 24th Oct |
Appendix 4G and Corporate Governance Statement |
| 24th Oct |
Annual Report to Shareholders |
| 20th Oct |
Annual Report to Shareholders |
| 20th Oct |
Appendix 4G and Corporate Governance Statement |
| 20th Oct |
Notice of Annual General Meeting/Proxy Form |
| 20th Oct |
Appendix 4C - Quarterly |
| 18th Oct |
Replacement Appendix 3B |
| 16th Oct |
Initial Director's Interest Notice |
| 13th Oct |
Appendix 3B |
| 13th Oct |
Prospectus |
| 10th Oct |
Net Tangible Asset Backing |
| 6th Oct |
$1.2M Capital Raising |
| 2nd Oct |
Update on Capital Raising |
| 27th Sep |
Suspension from Official Quotation |
| 25th Sep |
Trading Halt |
| 22nd Sep |
Omni Innovation Executes Chinese Licence Agreement |
| 20th Sep |
Net Tangible Asset Backing |
| 1st Sep |
Appendix 4E and Full Year Statutory Accounts |
| 28th Aug |
Revised Medical Honey Investment Structure |
| 16th Aug |
Omni Innovation Enters Chinese Distribution Agreement with Eagle Health |
| 14th Aug |
Net Tangible Asset Backing |
| 14th Aug |
Trading Halt |
| 31st Jul |
Appendix 4C - Quarterly |
| 14th Jul |
Net Tangible Asset Backing |
| 5th Jul |
Change of Director's Interest Notice x 3 |
| 4th Jul |
Prospectus |
| 4th Jul |
Appendix 3B |
| 26th Jun |
Results of General Meeting |
| 26th Jun |
Accelerating Portfolio Progress |
| 15th Jun |
Net Tangible Asset Backing |
| 31st May |
Investor Presentation |
| 30th May |
Southern Cross University Collaboration with Medic Honey |
| 25th May |
Notice of General Meeting/Proxy Form |
| 18th May |
Appointment of Leading Medicinal Cannabis Advisor |
| 12th May |
Net Tangible Asset Backing |
| 9th May |
Change in Substantial Holding |
| 9th May |
Change of Director's Interest Notice x 3 |
| 9th May |
Replacement Appendix 3B |
| 5th May |
Prospectus |
| 5th May |
Appendix 3B |
| 5th May |
EVE Capital Raising Completed |
| 3rd May |
EVE Capital Raising Oversubscribed |
| 2nd May |
Reinstatement to Official Quotation |
| 1st May |
Eve Invests in Pioneering Cannabis Honey & Tea Tree Oil Co |
| 28th Apr |
Appendix 4C - Quarterly |
| 21st Apr |
LNK: Change of Perth Address for Shareholder Purposes |
| 21st Apr |
Update on Capital Raising |
| 18th Apr |
Update on Capital Raising |
| 13th Apr |
Net Tangible Asset Backing |
| 10th Apr |
Update on Capital Raising |
| 3rd Apr |
Update on Capital Raising |
| 27th Mar |
Voluntary Suspension |
| 23rd Mar |
Trading Halt |
| 23rd Mar |
Omni Innovation - US Manufacturer Appointed |
| 22nd Mar |
Omni Innovation Completes UK Licence Agreement |
| 14th Mar |
Net Tangible Asset Backing |
| 8th Mar |
Omni Innovation US Update |
| 1st Mar |
Omni Innovation - US Patent Notice of Allowance Received |
| 28th Feb |
Omni Innovation Update |
| 28th Feb |
Half Yearly Report and Accounts |
| 14th Feb |
Results of Meeting |
| 13th Feb |
Net Tangible Asset Backing |
| 30th Jan |
Appendix 4C - Quarterly |
| 25th Jan |
Sales Results Exceed Expectations for Faulding GlucoControl |
| 17th Jan |
Change of Director's Interest Notice |
| 12th Jan |
Notice of General Meeting/Proxy Form |
| 11th Jan |
Net Tangible Asset Backing |
| 11th Jan |
Change in Substantial Holding |
